PROteolysis Targeting Chimeras: A new cutting‐edge nanomedicine for colorectal cancer DOI Creative Commons
Swastika Maitra, Nobendu Mukerjee, Dattatreya Mukherjee

et al.

Clinical and Translational Discovery, Journal Year: 2024, Volume and Issue: 4(4)

Published: July 4, 2024

Abstract Colorectal cancer (CRC) is a prevalent malignancy with high mortality rate, necessitating innovative treatment strategies. PROTACs (PROteolysis Targeting Chimeras) represent promising therapeutic approach by targeting and degrading oncogenic proteins via the ubiquitin‐proteasome pathway. This study explores potential of using exosomes as delivery vehicles for to enhance efficacy. Exosomes, due their biocompatibility inherent capabilities, offer precise method delivering CRC cells, potentially overcoming challenges associated traditional therapies such drug resistance off‐target effects. By harnessing advantages both exosome‐based PROTAC technology, this aims improve targeted protein degradation outcomes in treatment. Further research required optimize exosome engineering, ensure efficient loading, validate safety efficacy novel strategy through preclinical clinical trials.

Language: Английский

Neoadjuvant therapy for colorectal cancer from 2015 to 2024: a visual analysis and bibliometric analysis DOI Creative Commons

Boyu Kang,

Yihuan Qiao,

Junyong Zhu

et al.

Frontiers in Oncology, Journal Year: 2025, Volume and Issue: 15

Published: April 2, 2025

Colorectal cancer (CRC) imposes a substantial burden on global health., but research trends and hotspots in this field are still not clear. The purpose of is to create visual knowledge map based bibliometric analysis, identify predict future trends. Utilizing the Web Science Core Collection (WoSCC) as data source integrating visualization capabilities Bibliometrix R software package, CiteSpace, VOSviewer, analyze authors, institutions, countries, cited documents, publishing journals, abstracts, keyword information literature pertaining neoadjuvant therapy for colorectal spanning from January 2015 December 2024. analysis included 1,587 articles 1,464 385 61 countries or regions. China has largest number publications (449) citations (5,035). United States occupies leading position with an average 21.6. "Annals Surgical Oncology" most published journal 51 articles, "Journal Clinical references (4,465 references). Highly focus clinical trials guidelines cancer. In recent years, important keywords have been "artificial intelligence", "total therapy" "immunotherapy". This article provided review cancer, can provide reference subsequent results offered valuable insights that informed direction advancements.

Language: Английский

Citations

1
Targeting tumor-infiltrating CCR8+ regulatory T cells induces antitumor immunity through functional restoration of CD4+ Tconvs and CD8+ T cells in colorectal cancer DOI Creative Commons
Qian Chen, Meiying Shen, Min Yan

et al.

Journal of Translational Medicine, Journal Year: 2024, Volume and Issue: 22(1)

Published: July 30, 2024

Chemokine (C-C motif) receptor 8 (CCR8) is a chemokine selectively expressed on tumor-infiltrating regulatory T cells (Tregs). Strong immunosuppression mediated by CCR8

Language: Английский

Citations

9
Circ_RUSC2 Sequesters miR-661 and Elevates TUSC2 Expression to Suppress Colorectal Cancer Progression DOI Open Access
Yixin Shi,

Dingru Li,

Yunchao Xu

et al.

International Journal of Molecular Sciences, Journal Year: 2025, Volume and Issue: 26(7), P. 2937 - 2937

Published: March 24, 2025

Despite advancements in diagnostic efficiency, colorectal cancer (CRC) remains a leading cause of cancer-related mortality, with increasing incidence rates. Circular RNA (circRNA) is closed-loop, generally stable noncoding that functions as sponge for microRNAs CRC. The purpose this study was to investigate the function and underlying mechanism circ_RUSC2, new circRNA, expression levels miR-661, TUSC2 were assessed using qRT-PCR, Western blot, immunohistochemistry. Functional assays, including CCK-8, Transwell, scratch wound healing, performed evaluate cell proliferation, migration, invasion. pull-down actinomycin D assays used interactions stability. In both CRC cells tissues, miR-661 markedly elevated, while circ_RUSC2 considerably reduced. Poor differentiation, distant metastases, lymph node an advanced stage all strongly correlated either overexpression or downregulation. more compared its linear RUSC2 mRNA. invasion, proliferation suppressed by ectopic expression; inhibitory effect restored mimic. Circ_RUSC2 served miR-661's sponge. counteracted effects which stimulated At post-transcriptional level, controlled cells. comparison negative control, reduced, half-life shortened methyltransferase-like 3 (METTL3) knockdown. cytoplasmic circRNA. inhibits malignant phenotypes via miR-661/TUSC2 axis. onset progression are linked downregulation Circ_RUSC2. might become through N6-methyladenosine (m6A) methylation regulated METTL3. According our research, be biomarker treatment target

Language: Английский

Citations

0
PROteolysis Targeting Chimeras: A new cutting‐edge nanomedicine for colorectal cancer DOI Creative Commons
Swastika Maitra, Nobendu Mukerjee, Dattatreya Mukherjee

et al.

Clinical and Translational Discovery, Journal Year: 2024, Volume and Issue: 4(4)

Published: July 4, 2024

Abstract Colorectal cancer (CRC) is a prevalent malignancy with high mortality rate, necessitating innovative treatment strategies. PROTACs (PROteolysis Targeting Chimeras) represent promising therapeutic approach by targeting and degrading oncogenic proteins via the ubiquitin‐proteasome pathway. This study explores potential of using exosomes as delivery vehicles for to enhance efficacy. Exosomes, due their biocompatibility inherent capabilities, offer precise method delivering CRC cells, potentially overcoming challenges associated traditional therapies such drug resistance off‐target effects. By harnessing advantages both exosome‐based PROTAC technology, this aims improve targeted protein degradation outcomes in treatment. Further research required optimize exosome engineering, ensure efficient loading, validate safety efficacy novel strategy through preclinical clinical trials.

Language: Английский

Citations

1